CN102008571A - Traditional Chinese medicine composition as well as preparation method and application thereof - Google Patents
Traditional Chinese medicine composition as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN102008571A CN102008571A CN 201010559672 CN201010559672A CN102008571A CN 102008571 A CN102008571 A CN 102008571A CN 201010559672 CN201010559672 CN 201010559672 CN 201010559672 A CN201010559672 A CN 201010559672A CN 102008571 A CN102008571 A CN 102008571A
- Authority
- CN
- China
- Prior art keywords
- extract
- preparation
- radix
- chinese medicine
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition, comprising the following effective medicament components in parts by weight: 1-5 parts of epimedium herb extract, 1-5 parts of kudzu root extract, 1-5 parts of radix astragali extract, 0.5-2 parts of hawthorn leaf extract, 0.1-0.3 part of radix pseudo-ginseng extract and 0.3-0.7 part of cassia twig extract. The invention also provides a preparation method and an application of the traditional Chinese medicine composition. The traditional Chinese medicine composition utilizes the epimedium herb extract, the kudzu root extract and the radix astragali extract as main components, and is additionally provided with the hawthorn leaf extract, the radix pseudo-ginseng extract and the cassia twig extract, and the effective components are mutually complemented to achieve the functions of mutual synergy and improved curative effect. The obtained traditional Chinese medicine composition has obvious curative effect and no obvious toxic or side effect. The preparation method in the invention is simple in operation, and the obtained composition has good curative effect which is obviously superior to that of the existing drug when being used for curing myocardial ischemia, and has practicability.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition and its production and application, be specifically related to a kind of medicine for the treatment of myocardial ischemia and its production and application.
Background technology
Myocardial ischemia is meant that the hemoperfusion of heart reduces, and causes the oxygen supply of heart to reduce, and energy metabolism of myocardial is undesired, can not support a kind of pathological state of heart operate as normal.Clinical demonstration causes main, the modal cause of disease of myocardial ischemia, is that coronary artery (accidental pulmonary artery) is narrow.And the main cause of coronary stricture is an atherosclerosis.The heart disease that causes because of coronary atherosclerosis is exactly the coronary heart disease that the big daily life of a family is said.So coronary heart disease is myocardial ischemia " arch-criminal ".
Myocardial ischemia all may bring many adverse effects to heart and whole body.Myocardial ischemia can directly cause anoxia, and energy essential when making cardiomotility is under-supply, and metabolic refuse can not be removed effectively in time, finally can influence the contractile function of heart.Myocardial ischemia also can damage diastolic function.Shrink bad and diastole is bad combines, easily cause ventricular filling pressure to raise, cause pulmonary congestion, can cause that also complicated substance metabolism is disorderly and myocardial electrical activity is not normal.Therefore,, cause of disease symptomatic treatment should be found accurately, just potential serious consequence can be avoided in case myocardial ischemia occurs.The medicine for the treatment of myocardial ischemia now has a lot, but curative effect can not be satisfactory, and takes for a long time and can produce certain toxic and side effects to human body.
Summary of the invention
The present invention is directed to above-mentioned deficiency, a kind of Chinese medicine composition is provided, this Chinese medicine composition position pure plant extracts, evident in efficacy, no obvious toxic-side effects.
The present invention also provides the preparation method of this Chinese medicine composition.
The present invention also provides the application of this Chinese medicine composition in the treatment myocardial ischemia.
The present invention is achieved by the following measures:
A kind of Chinese medicine composition is characterized in that effective ingredient comprises the raw material of following weight portion:
Herba Epimedii extract 1-5 part, Radix Puerariae extract 1-5 part, Radix Astragali extract 1-5 part, Folium Crataegi extract 0.5-2 part, Radix Notoginseng extract 0.1-0.3 part, Ramulus Cinnamomi extract 0.3-0.7 part;
Described Herba Epimedii extract and Radix Puerariae extract are Herba Epimedii or the Radix Puerariae extract through ethanol extraction, macroporous resin adsorption gained, Folium Crataegi extract and Radix Astragali extract are the water extract of the Fructus Crataegi or the Radix Astragali, Radix Notoginseng extract is the ethanol extraction of Radix Notoginseng, and Ramulus Cinnamomi extract adopts the extract of steam distillation gained for the Ramulus Cinnamomi decoction pieces.
The optimization formula of above-mentioned Chinese medicine composition is (weight portion): 2 parts of Herba Epimedii extracts, 2 parts of Radix Puerariae extracts, 2 parts of Radix Astragali extracts, 1 part of Folium Crataegi extract, 0.2 part of Radix Notoginseng extract, 0.5 part of Ramulus Cinnamomi extract.
The dosage form of above-mentioned Chinese medicine composition is tablet or capsule.
The preparation method of above-mentioned Chinese medicine composition is characterized in that may further comprise the steps:
(1) preparation of each extract
A. the preparation of Herba Epimedii extract: twice of the alcohol reflux that Herba Epimedii is added 5-6 quality 50-70wt% doubly, each 2～3 hours, merge extractive liquid,, reclaim ethanol and be concentrated into an amount of, after centrifugal with the supernatant absorption with macroporous adsorbent resin, water is got express developed then, the ethanol elution of reuse 50-70wt%, collect ethanol elution, eluent reclaims and to carry out spray drying behind the ethanol or with the eluent thick paste that to be condensed into 80 ℃ of following relative densities be 1.30-1.31,60 ℃ of vacuum decompression dryings get Herba Epimedii extract;
B. the preparation of Radix Puerariae extract: Radix Puerariae is cut into slices, the alcohol heating reflux that adds 6-7 quality 60-70wt% doubly extracts twice, each 2-3h, merge extractive liquid,, reclaim ethanol and be concentrated into an amount of, after centrifugal with the supernatant absorption with macroporous adsorbent resin, water is got express developed then, the ethanol elution of reuse 50-70wt%, collect ethanol elution, eluent reclaims and to carry out spray drying behind the ethanol or with the eluent thick paste that to be condensed into 80 ℃ of following relative densities be 1.30-1.31,60 ℃ of vacuum decompression dryings, Radix Puerariae extract;
C. the preparation of Radix Astragali extract: the Radix Astragali is added 10 quality decocting doubly boil 2 times, each 1.5h filters the back and merges twice filtrate, carries out spray drying or 60 ℃ of vacuum dryings after the concentrating under reduced pressure filtrate, Radix Astragali extract;
D. the preparation of Folium Crataegi extract: Folium Crataegi is embathed totally with clear water and deionized water, remove rhizome after drying, get leaf and partly use 20 quality times deionized water digestion 1 h, after the filtration filtrate lyophilization is got Folium Crataegi extract;
E. the preparation of Radix Notoginseng extract: Radix Notoginseng is mixed with 6-10 quality 30-60% ethanol doubly, twice of 70 ℃ of heating and refluxing extraction, each 40 min that extract, merge extracted twice liquid, reclaim and to carry out spray drying behind the ethanol or the extracting solution thick paste that to be condensed into 80 ℃ of following relative densities be 1.30-1.31,60 ℃ of drying under reduced pressure get Radix Notoginseng extract;
F. the preparation of Ramulus Cinnamomi extract: the Ramulus Cinnamomi decoction pieces is extracted volatile oil with steam distillation, the thick paste that it is 1.30-1.31 that distillate is condensed into 80 ℃ of following relative densities, spray drying or 60 ℃ of vacuum decompression dryings get Ramulus Cinnamomi extract;
(2) preparation of granule or tablet: get above-mentioned various extract in proportion; with the abundant mix homogeneously of adjuvant; cross 100 mesh sieves; PVPP with recipe quantity 1/3 presses the abundant mix homogeneously of method that equivalent drips then; cross 100 mesh sieves; with 95wt% ethanol system soft material, cross 24 mesh sieves, make granule or tablet forming.
The present invention also provides the application of above-mentioned Chinese medicine composition in the treatment myocardial ischemia, and this curative effect of medication is remarkable, is better than existing medicine when treatment myocardial ischemia disease.
The usage of Chinese medicine composition of the present invention is oral, and consumption is every day 2-3 time, each 0. 6-1.8g, and described Chinese medicine composition does not have obvious toxic-side effects, does not have obviously taboo in use.
Radix Notoginseng extract, warm in nature, sweet in the mouth, little hardship, chemical constituent are mainly ginsenoside Rb1, Rg1, Rg2 and a small amount of ginsenoside Ra, Rb2, Rb and Re for containing Saponin, in addition, still contain flavonoid glycoside, starch, protein, oils and fats etc.Have the promoting blood circulation to remove blood stasis effect, expand blood vessel, blood pressure lowering, can antiplatelet aggregation, antithrombotic forms, resists myocardial ischemia, anti-cerebral ischemia, arrhythmia, antiatherogenic drug action.Folium Crataegi extract, the circulation of qi promoting dissipating blood stasis can antiplatelet aggregation, antithrombotic forms, resists myocardial ischemia, anti-cerebral ischemia, arrhythmia, antiatherogenic drug action.Herba Epimedii extract, warming and recuperating the kidney-YANG can obviously reduce Peripheral resistance, and left chamber output is increased, and reduces cardiac load, increases peripheral organ's perfusion, and arrhythmia can also improve cerebral ischemia and cerebral anoxia, improves hypoxia-bearing capability.Radix Puerariae extract has the yang invigorating expelling pathogenic factors from muscles, resists myocardial ischemia, arrhythmia, expansion blood vessel, blood pressure lowering, improve hemorheological property and antithrombotic effect.Radix Astragali extract has during QI invigorating builds, arrhythmia, resist myocardial ischemia, multiple effect such as blood pressure regulation, diuresis, enhancing human body immunity function.Ramulus Cinnamomi extract has antalgic, supporing yang activating QI, and blood vessel dilating is regulated sanguimotor effect.
This Chinese medicine composition is a main component with Herba Epimedii extract, Radix Puerariae extract and Radix Astragali extract, be aided with Folium Crataegi extract, Radix Notoginseng extract and Ramulus Cinnamomi extract, by auxilliary mutually the helping each other between each effective ingredient, play collaborative mutually, as to improve curative effect effect, the Chinese medicine composition of gained obvious toxic-side effects evident in efficacy, no.Method of the present invention is simple to operate, and the gained curative effect of medication is good, and curative effect obviously is better than existing medicine when being used for the myocardial ischemia disease, has practicality.
The specific embodiment
The present invention will be further elaborated below in conjunction with specific embodiment, should be understood that, following explanation only is in order to explain the present invention, its content not to be limited.
Embodiment 1
Herba Epimedii extract 2g, Radix Puerariae extract 2g, Radix Astragali extract 2g, Folium Crataegi extract 1g, Radix Notoginseng extract 0.2g, Ramulus Cinnamomi extract 0.5g.
Preparation method is:
1, the preparation of each medicinal substances extract
A. the preparation of Radix Notoginseng extract: Radix Notoginseng is mixed with 6-10 quality 30-60% ethanol doubly, twice of 70 ℃ of heating and refluxing extraction, each 40 min that extract, merge extracted twice liquid, carry out spray drying or be condensed into 80 ℃ of following relative densities the thick paste that is 1.30-1.31 after reclaiming ethanol, 60 ℃ of drying under reduced pressure get Radix Notoginseng extract;
B. the preparation of Folium Crataegi extract: Folium Crataegi is embathed totally with clear water and deionized water, remove rhizome after drying, get leaf and partly use 20 quality times deionized water digestion 1 h, after the filtration filtrate lyophilization is got Folium Crataegi extract;
C. the preparation of Radix Astragali extract: the Radix Astragali is added 10 quality decocting doubly boil 2 times, each 1.5h filters the back and merges twice filtrate, carries out spray drying or 60 ℃ of vacuum dryings after the concentrating under reduced pressure filtrate, Radix Astragali extract;
D. the preparation of Radix Puerariae extract: Radix Puerariae is cut into slices, the alcohol heating reflux that adds 6-7 quality 60-70wt% doubly extracts twice, each 2-3h, merge extractive liquid,, reclaim ethanol and be concentrated into an amount of, after centrifugal with the supernatant absorption with macroporous adsorbent resin, water is got express developed then, the ethanol elution of reuse 50-70wt%, collect ethanol elution, reclaim and to carry out spray drying behind the ethanol or the eluent thick paste that to be condensed into 80 ℃ of following relative densities be 1.30-1.31,60 ℃ of vacuum decompression dryings, Radix Puerariae extract;
E. the preparation of Herba Epimedii extract: twice of the alcohol reflux that Herba Epimedii is added 5-6 quality 50-70wt% doubly, each 2～3 hours, merge extractive liquid,, reclaim ethanol and be concentrated into an amount of, after centrifugal with the supernatant absorption with macroporous adsorbent resin, water is got express developed then, the ethanol elution of reuse 50-70wt%, collect ethanol elution, reclaim and to carry out spray drying behind the ethanol or the eluent thick paste that to be condensed into 80 ℃ of following relative densities be 1.30-1.31,60 ℃ of vacuum decompression dryings get Herba Epimedii extract;
F. the preparation of Ramulus Cinnamomi extract: the Ramulus Cinnamomi decoction pieces is extracted volatile oil with steam distillation, the thick paste that it is 1.30-1.31 that distillate is condensed into 80 ℃ of following relative densities, spray drying or 60 ℃ of vacuum decompression dryings get Ramulus Cinnamomi extract;
2, the preparation of preparation: get above-mentioned various extract in proportion,, cross 100 mesh sieves with the abundant mix homogeneously of adjuvant, PVPP with recipe quantity 1/3 presses the abundant mix homogeneously of method that equivalent drips then, crosses 100 mesh sieves, with 95wt% ethanol system soft material, cross 24 mesh sieves, tablet forming.
Embodiment 2
Herba Epimedii extract 1g, Radix Puerariae extract 3g, Radix Astragali extract 5g, Folium Crataegi extract 1g, Radix Notoginseng extract 0.1g, Ramulus Cinnamomi extract 0.4g.
Preparation method is with embodiment 1.
Embodiment 3
Herba Epimedii extract 5g, Radix Puerariae extract 1g, Radix Astragali extract 1g, Folium Crataegi extract 2g, Radix Notoginseng extract 0.3g, Ramulus Cinnamomi extract 0.7g.
Preparation method is with embodiment 1.
Embodiment 4
Herba Epimedii extract 3g, Radix Puerariae extract 5g, Radix Astragali extract 3g, Folium Crataegi extract 0.5g, Radix Notoginseng extract 0.2g, Ramulus Cinnamomi extract 0.3g.
Preparation method is with embodiment 1, and different is to make granule.
Below medicine of the present invention is carried out following zoopery
1, to the influence of hybrid dog myocardial infarction and ischemia model
1.1 experiment medicine
Experimental group is the medicine of the embodiment of the invention 1, and matched group is an XUESAITONG PIAN, and XUESAITONG PIAN is mainly the effective site Radix Notoginseng total arasaponins that the araliaceae ginseng plant Radix Notoginseng is extracted.
1.2 drug dose
The experimental group drug dose is respectively 200 mg/kg, 100 mg/kg, 50 mg/kg; The matched group consumption is 40 mg/kg.
1.3 experimental technique
Get 30 of hybrid dogs, be divided into 5 groups at random, anaesthetize with 30mg/kg pentobarbital sodium iv, back of the body position is fixing, and skin of neck cuts, tracheal intubation, connect SC23 type artificial respirator, the 4th intercostal is executed thoracotomy in the left side, exposes heart, cut off pericardium, separate 1/3 place under the left anterior descending coronary artery, ligation behind the threading, the preparation myocardial infarction model, adopt multiple spot cloth formula absorption method mapping multi-lead electrocardiogram (EECG), 24 of mapping points, a sham operated rats not ligation of threading.Near infarct, select 12 mapping points, and selecting 1 control point away from infarct, hand-held insulated metal point-like electrode carries out mapping by the mapping dot sequency, through pick off JB-642G, amplifier AB-621G, lead physiograph record epicardial electrogram EECG, calibration: 1mm=1mv with eight.After 15min and the administration 5,15,30,60,90 and the EECG of 120min, add up each punctuate ST field offset summation ∑-ST, and the ST section is raised 〉=the above number N-ST of 2mv after the record ligation.Each group is got blood respectively at 60min femoral vein after 15min and the administration before the ligation, after the ligation, with kit measurement serum CK, LDH value.After experiment finishes, take out heart immediately, with normal saline flush away blood, take by weighing heavy whole-heartedly heavy with ventricle, and the ventricle crosscut become the U sheet, and place 37 ℃ of 1%TTC solution 10min that dyes, cut off the non-infarct that each myocardium sheet is colored, undyed infarct cardiac muscle is weighed, obtain infarction size heavily respectively divided by ventricle and account for the heavy percentage rate of ventricle.Experimental data is all represented with X ± S, relatively adopts the t check between group.
1.4 experimental result
Experiment confirm, the medicine of 3 dosage of the present invention to cardiac muscle stalk due to the anesthetized dog coronary ligation protective effect all be better than XUESAITONG, illustrate that the present invention and XUESAITONG compare myocardial infarction and have significant protective effect.
2. to the influence of rat heart muscle ischemia model
2.1 experiment medicine
Experimental group is a medicine of the present invention, and matched group is a FUFANG DANSHEN PIAN, and the FUFANG DANSHEN PIAN ingredient is mainly Radix Salviae Miltiorrhizae, Radix Notoginseng, Borneolum Syntheticum.
2.2 drug dose
The experimental group drug dose is respectively 200 mg/kg, 100 mg/kg, 50 mg/kg; The matched group consumption is 100 mg/kg.
2.3 experimental technique:
60 of wistar rats are divided into 6 groups at random: model group, sham operated rats, 200mg/kg, 100 mg/kg, 50mg/kg dosage experiments group, matched group.Model group, sham operated rats are irritated stomach and are given distilled water 10ml/kg, and all the other each groups are irritated stomach and given relative medicine.Once a day, successive administration 7d, 60min behind the last medicine, with 20% urethane intraperitoneal anesthesia rat (0.5ml/100g), at the about 2cm of left mid-clavicular line longitudinal incision skin, open the thoracic cavity at the 4th and the 5th intercostal, cut off pericardium, (only not ligation of threading of sham operated rats) closes the thoracic cavity rapidly behind ligation left coronary artery between arterial cone and the left auricle.Reach postoperative 120 min before the art and write down rat front electrocardiogram (ECG) respectively, measure the S-T section and change.Postoperative 2 h win rat heart, and NS washes residual to the greatest extent blood with ice; Blot with filter paper, weigh, coring, 0.1 g is freezing rapidly for the point tissue, left ventricle is cut into the thick thin slice of 1-2 mm, with 0.1% chlorination nitro blue tetrazolium (NBT) dyeing 15mi (37 ℃ ± 0.5 ℃), cut the myocardial infarction district that is not colored after the taking-up, blot with filter paper, weigh, calculate infarcted myocardium and account for heavy whole-heartedly percentage rate.Prepare myocardium homogenate with 0.9% normal saline, measure active, malonaldehyde (MDA) content of creatine phosphokinase (CPK), superoxide dismutase (SOD) in the myocardium homogenate.All data are carried out statistical procedures with SPSS11.0 software, all represent t check between relatively employing group of every index with x ± s form.
2.4 experimental result
1. to the influence of rats with myocardial ischemia electrocardiogram S-T section and myocardial infarction area: model group electrocardiogram S-T section is significantly raised, infarct size is 24.76%, relatively has significant difference (P＜0.01) with sham operated rats, the ECG S-T section of 100mg/kg, 200mg/kg dosage experiments group and FUFANG DANSHEN PIAN group significantly reduces, infarct size reduces, relatively have significant difference (P＜0.05 or P＜0.01) with model group, experimental group low dose group S-T section and model group be there was no significant difference relatively.The results are shown in Table 4 and table 5.
2. experimental group is to the influence of ischemic myocardium SOD, MDA: model group rat heart muscle SOD is active significantly to be reduced, and MDA content significantly increases, and relatively has significant difference with sham operated rats.50mg/kg, 100mg/kg, 200mg/kg dosage experiments group group and FUFANG DANSHEN PIAN group, SOD is active to be increased, and MDA content reduces, and relatively has significant difference (P＜0.05 or P＜0.01) with model group.Experimental group is better than the FUFANG DANSHEN PIAN group, the results are shown in Table 6.
3. experimental group significantly reduces the model group rat heart muscle CPK activity that influences of ischemic myocardium CPK, and relatively has significant difference (P＜0.01) with sham operated rats.50mg/kg, 100mg/kg, 200mg/kg dosage experiments group and FUFANG DANSHEN PIAN group, CPK is active to be increased, and relatively has significant difference (P＜0.05 or P＜0.01) with model group.Experimental group is better than FUFANG DANSHEN PIAN, the results are shown in Table 7.
3, conclusion: above data declaration the drug action of treatment myocardial ischemia of medicine of the present invention obviously be better than FUFANG DANSHEN PIAN.
Clinical trial
1, case source
The patient that random choose 150 examples have the myocardial ischemia disease in this city hospital wherein, is equally divided into 5 groups, and the 1-4 group adopts the medicine of embodiment 1-4 respectively, and the 5th group is adopted XUESAITONG medicine in contrast.Wherein, the 1st group of male's 15 examples, women's 15 examples, 18～60 years old age, the course of disease 1～10 year; The 2nd group of male's 13 examples, women's 17 examples, 18～60 years old age, course of disease 1-10; The 3rd group of male's 11 examples, women's 19 examples, age 18-60 year, course of disease 1-10; The 4th group of male's 17 examples, women's 13 examples, 18～63 years old age, course of disease 1-10; The 5th group of male's 18 examples, women's 12 examples, age 18-60 year, course of disease 1-10.
2, Therapeutic Method
The each medicine 0.6g that uses of 1-4 group, every day 3 times, the 5th group is used medicine 0.1g at every turn, every day 3 times.Each group was taken medicine 30 days.
3, curative effect is judged
Produce effects: angina pectoris obviously improves, and does not have angina pectoris substantially or number of times obviously reduces, and electrocardiogram obviously improves or recovers normal;
Effectively: angina pectoris improves, and no angina pectoris number of times reduces, and electrocardiogram improves;
Invalid: angina pectoris does not have improvement substantially, and electrocardiogram does not have obvious improvement.
4, therapeutic outcome
Model case:
Mr. Zhang 40 years old, suffered from coronary heart disease 10 years, take the medicine 10 days of the embodiment of the invention 1, electrocardiogram obviously improves, and takes medicine 20 days, the nitroglycerin number of applications drops to 0-1 time by 4-5 time weekly, after taking medicine 40 days, it is normal that electrocardiogram recovers, the basic nitroglycerin of stopping using, angina pectoris is reduced to 0-1 time by 3-4 time weekly, took medicine 5 years, and do not seen untoward reaction.
Mrs Li 58 years old, suffered from coronary heart disease 6 years, the medicine of the embodiment of the invention of taking medicine 3 15 days, electrocardiogram obviously improves, and takes medicine 30 days, the nitroglycerin number of applications drops to 0-1 time by 3-4 time weekly, after taking medicine 60 days, it is normal that electrocardiogram recovers, the basic nitroglycerin of stopping using, angina pectoris is reduced to 0-1 time by 3-4 time weekly, took medicine 3 years, and do not seen untoward reaction.
Mrs Wang 55 years old, suffered from coronary heart disease 5 years, take the medicine 15 days of the embodiment of the invention 4, electrocardiogram obviously improves, and takes medicine 30 days, the nitroglycerin number of applications drops to 0-1 time by 2-3 time weekly, after taking medicine 40 days, it is normal that electrocardiogram recovers, the basic nitroglycerin of stopping using, angina pectoris is reduced to 0-1 time by 2-3 time weekly, took medicine 3 years, and do not seen untoward reaction.
Mr. Xie 38 years old, suffered from coronary heart disease 2 years, take the medicine 10 days of the embodiment of the invention 2, electrocardiogram obviously improves, and takes medicine 20 days, the nitroglycerin number of applications drops to 0-1 time by 2-3 time weekly, after taking medicine 30 days, it is normal that electrocardiogram recovers, the basic nitroglycerin of stopping using, angina pectoris is reduced to 0-1 time by 2-3 time weekly, took medicine 3 years, and do not seen untoward reaction.
Claims (5)
1. Chinese medicine composition is characterized in that effective ingredient comprises the raw material of following weight portion:
Herba Epimedii extract 1-5 part, Radix Puerariae extract 1-5 part, Radix Astragali extract 1-5 part, Folium Crataegi extract 0.5-2 part, Radix Notoginseng extract 0.1-0.3 part, Ramulus Cinnamomi extract 0.3-0.7 part;
Described Herba Epimedii extract and Radix Puerariae extract are Herba Epimedii or the Radix Puerariae extract through ethanol extraction, macroporous resin adsorption gained, Folium Crataegi extract and Radix Astragali extract are the water extract of the Fructus Crataegi or the Radix Astragali, Radix Notoginseng extract is the ethanol extraction of Radix Notoginseng, and Ramulus Cinnamomi extract adopts the extract of steam distillation gained for the Ramulus Cinnamomi decoction pieces.
2. Chinese medicine composition according to claim 1 is characterized in that effective ingredient comprises the raw material of following weight portion: 2 parts of Herba Epimedii extracts, 2 parts of Radix Puerariae extracts, 2 parts of Radix Astragali extracts, 1 part of Folium Crataegi extract, 0.2 part of Radix Notoginseng extract, 0.5 part of Ramulus Cinnamomi extract.
3. Chinese medicine composition according to claim 1 and 2 is characterized in that: described Chinese medicine composition dosage form is tablet or capsule.
4. the preparation method of the described Chinese medicine composition of claim 1 is characterized in that may further comprise the steps:
(1) preparation of each extract
A. the preparation of Herba Epimedii extract: twice of the alcohol reflux that Herba Epimedii is added 5-6 quality 50-70wt% doubly, each 2～3 hours, merge extractive liquid,, reclaim ethanol and be concentrated into an amount of, after centrifugal with the supernatant absorption with macroporous adsorbent resin, water is got express developed then, the ethanol elution of reuse 50-70wt%, collect ethanol elution, eluent reclaims and to carry out spray drying behind the ethanol or with the eluent thick paste that to be condensed into 80 ℃ of following relative densities be 1.30-1.31,60 ℃ of vacuum decompression dryings get Herba Epimedii extract;
B. the preparation of Radix Puerariae extract: Radix Puerariae is cut into slices, the alcohol heating reflux that adds 6-7 quality 60-70wt% doubly extracts twice, each 2-3h, merge extractive liquid,, reclaim ethanol and be concentrated into an amount of, after centrifugal with the supernatant absorption with macroporous adsorbent resin, water is got express developed then, the ethanol elution of reuse 50-70wt%, collect ethanol elution, eluent reclaims and to carry out spray drying behind the ethanol or with the eluent thick paste that to be condensed into 80 ℃ of following relative densities be 1.30-1.31,60 ℃ of vacuum decompression dryings, Radix Puerariae extract;
C. the preparation of Radix Astragali extract: the Radix Astragali is added 10 quality decocting doubly boil 2 times, each 1.5h filters the back and merges twice filtrate, carries out spray drying or 60 ℃ of vacuum dryings after the concentrating under reduced pressure filtrate, Radix Astragali extract;
D. the preparation of Folium Crataegi extract: Folium Crataegi is embathed totally with clear water and deionized water, remove rhizome after drying, get leaf and partly use 20 quality times deionized water digestion 1 h, after the filtration filtrate lyophilization is got Folium Crataegi extract;
E. the preparation of Radix Notoginseng extract: Radix Notoginseng is mixed with 6-10 quality 30-60% ethanol doubly, twice of 70 ℃ of heating and refluxing extraction, each 40 min that extract, merge extracted twice liquid, reclaim and to carry out spray drying behind the ethanol or the extracting solution thick paste that to be condensed into 80 ℃ of following relative densities be 1.30-1.31,60 ℃ of drying under reduced pressure get Radix Notoginseng extract;
F. the preparation of Ramulus Cinnamomi extract: the Ramulus Cinnamomi decoction pieces is extracted volatile oil with steam distillation, the thick paste that it is 1.30-1.31 that distillate is condensed into 80 ℃ of following relative densities, spray drying or 60 ℃ of vacuum decompression dryings get Ramulus Cinnamomi extract;
(2) preparation of granule or tablet: get above-mentioned various extract in proportion; with the abundant mix homogeneously of adjuvant; cross 100 mesh sieves; PVPP with recipe quantity 1/3 presses the abundant mix homogeneously of method that equivalent drips then; cross 100 mesh sieves; with 95wt% ethanol system soft material, cross 24 mesh sieves, make granule or tablet forming.
5. the application of the described Chinese medicine composition of claim 1 in the treatment myocardial ischemia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105596728A CN102008571B (en) | 2010-11-26 | 2010-11-26 | Traditional Chinese medicine composition as well as preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105596728A CN102008571B (en) | 2010-11-26 | 2010-11-26 | Traditional Chinese medicine composition as well as preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102008571A true CN102008571A (en) | 2011-04-13 |
| CN102008571B CN102008571B (en) | 2012-05-02 |
Family
ID=43839033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010105596728A Expired - Fee Related CN102008571B (en) | 2010-11-26 | 2010-11-26 | Traditional Chinese medicine composition as well as preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102008571B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105250998A (en) * | 2015-10-30 | 2016-01-20 | 上海善力健生物科技有限公司 | Biological agent for reducing blood pressure and preparation method of biological agent |
| CN115998803A (en) * | 2023-01-09 | 2023-04-25 | 南京中医药大学翰林学院 | Pharmaceutical composition for improving myocardial ischemia reperfusion injury and preparation method and application thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1334121A (en) * | 2001-08-31 | 2002-02-06 | 石家庄以岭药业有限公司 | Medicinal composition for restoring cardiac collaterals and its application |
| CN1347709A (en) * | 2000-10-09 | 2002-05-08 | 王学勇 | Cardiac and cerebral vascular disease treating medicine |
| CN1413601A (en) * | 2001-10-22 | 2003-04-30 | 孟宪茹 | Chinese medicine for compound circulation treatment of angiocardiopathy and cerebrovascular disease |
| CN1437959A (en) * | 2002-02-10 | 2003-08-27 | 杨志东 | Chinese prepartory for treating cardiovascular and cerebrovascular disease and preparation method |
| CN1857664A (en) * | 2006-04-11 | 2006-11-08 | 北京阜康仁生物制药科技有限公司 | Apoplexy treating preparation and its preparing process |
| CN1891279A (en) * | 2005-07-06 | 2007-01-10 | 陈克治 | Capsule for treating cardio-cerebrovasular disease |
| CN101306138A (en) * | 2007-05-15 | 2008-11-19 | 徐泽明 | Chinese traditional injection preparation for treating chest stuffiness and pains and its preparation method |
-
2010
- 2010-11-26 CN CN2010105596728A patent/CN102008571B/en not_active Expired - Fee Related
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1347709A (en) * | 2000-10-09 | 2002-05-08 | 王学勇 | Cardiac and cerebral vascular disease treating medicine |
| CN1334121A (en) * | 2001-08-31 | 2002-02-06 | 石家庄以岭药业有限公司 | Medicinal composition for restoring cardiac collaterals and its application |
| CN1413601A (en) * | 2001-10-22 | 2003-04-30 | 孟宪茹 | Chinese medicine for compound circulation treatment of angiocardiopathy and cerebrovascular disease |
| CN1437959A (en) * | 2002-02-10 | 2003-08-27 | 杨志东 | Chinese prepartory for treating cardiovascular and cerebrovascular disease and preparation method |
| CN1891279A (en) * | 2005-07-06 | 2007-01-10 | 陈克治 | Capsule for treating cardio-cerebrovasular disease |
| CN1857664A (en) * | 2006-04-11 | 2006-11-08 | 北京阜康仁生物制药科技有限公司 | Apoplexy treating preparation and its preparing process |
| CN101306138A (en) * | 2007-05-15 | 2008-11-19 | 徐泽明 | Chinese traditional injection preparation for treating chest stuffiness and pains and its preparation method |
Non-Patent Citations (2)
| Title |
|---|
| 《右江民族医学院学报》 20021031 邓宝澄 不稳定性心绞痛中医治疗概况 第24卷, 第5期 2 * |
| 《实用中医药杂志》 20060430 心痛灵口服液治疗冠心病心绞痛360例观察 王昃睿等 第22卷, 第4期 2 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105250998A (en) * | 2015-10-30 | 2016-01-20 | 上海善力健生物科技有限公司 | Biological agent for reducing blood pressure and preparation method of biological agent |
| CN115998803A (en) * | 2023-01-09 | 2023-04-25 | 南京中医药大学翰林学院 | Pharmaceutical composition for improving myocardial ischemia reperfusion injury and preparation method and application thereof |
| CN115998803B (en) * | 2023-01-09 | 2023-11-17 | 南京中医药大学翰林学院 | Pharmaceutical composition for improving myocardial ischemia reperfusion injury and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102008571B (en) | 2012-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101524421B (en) | Traditional Chinese medicine preparation for treating cardiovascular and cerebrovascular diseases | |
| CN101507765B (en) | Medicine for treating cerebrovascular disease and sequela thereof and preparation method thereof | |
| CN101502588B (en) | Composition for beauty treatment and removing blain and method for preparing the same | |
| CN102475830B (en) | Medicinal composition for treating coronary disease and angina pectoris, preparation method thereof and preparation thereof | |
| CN102552696A (en) | Compound diabetes oral preparation and preparation method thereof | |
| CN101088546A (en) | Heart-benefiting Yixinshu micropill and its prepn process | |
| CN101623354A (en) | Functional food of Chinese medicament preparation for preventing and treating cardiovascular and cerebrovascular disease and preparation method thereof | |
| CN102008571B (en) | Traditional Chinese medicine composition as well as preparation method and application thereof | |
| CN103479754B (en) | Hypotensive drug and preparation method thereof | |
| CN100488539C (en) | Pharmaceutical composition for promoting blood circulation and preparation method thereof | |
| CN102805807B (en) | Traditional Chinese medical composition for treating coronary heart disease and preparation method and applications thereof | |
| CN103919910A (en) | Medicine for treating coronary heart disease | |
| CN101637571B (en) | Traditional Chinese medicine preparation for treating heart cerebrovascular diseases and preparation method thereof | |
| CN1970050B (en) | Pharmaceutical composition for treating arrhythmia and preparation process thereof | |
| CN103933216B (en) | A kind of compound blood pressure reducing capsule for treating metabolic high blood pressure and its preparation and application | |
| CN106421293A (en) | Traditional Chinese medicine effective part composition for treating cardiovascular and cerebrovascular diseases | |
| CN100484542C (en) | Chinese medicinal compound recipe for treating osteoporosis and its preparing process | |
| CN1292784C (en) | Gandanqing capsule | |
| CN105343761A (en) | Traditional Chinese medicine composition for treating myocardial infarction and preparation method thereof | |
| CN101199568A (en) | Medicament compound for treating cardiovascular disease and preparing method thereof | |
| CN104740054A (en) | Pharmaceutical composition for treating myocardial ischemia as well as preparation method and use of pharmaceutical composition | |
| CN1321484A (en) | Medicine for curing coronary heart disease with hypertension and its preparation process | |
| CN105596420A (en) | Application of salviae miltiorrhizae and panax notoginseng composition and preparation method | |
| CN103768349A (en) | Application of four-component fructus cinnamoii preparation in preparing drugs for treatment of cerebrovascular and related diseases | |
| CN106138795A (en) | Chinese medicine composition for the treatment of premature beat and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120502 Termination date: 20141126 |
|
| EXPY | Termination of patent right or utility model |